CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lotem, J.
Right arrow Articles by Sachs, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotem, J.
Right arrow Articles by Sachs, L.

Cell Growth & Differentiation, Vol 4, Issue 1 41-47, Copyright © 1993 by American Association of Cancer Research


ARTICLES

Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells

J Lotem and L Sachs
Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.

Myeloid leukemias that differ in their competence for induction of differentiation were analyzed for expression of bcl-2 and c-myc and for their sensitivity to induction of apoptosis by heat shock and cancer chemotherapy compounds. The M1 leukemia expressed a high level of bcl-2 and showed a much lower susceptibility to induction of apoptosis by heat shock, Adriamycin, 1-beta-D-arabinofuranosylcytosine, methotrexate, and cycloheximide, compared to five other leukemias which expressed a low level of bcl-2. There was no association between susceptibility to induction of apoptosis and competence for induction of differentiation. The difference in susceptibility to methotrexate, which is not regulated by the multidrug resistance (MDR) genes, and treatment with verapamil, which blocks MDR activity, have indicated that the higher resistance of the M1 leukemia to these agents was not due to MDR activity. The results indicate that the level of regulated bcl-2 expression in these myeloid leukemias was associated with cell susceptibility to induction of apoptosis by different apoptosis-inducing agents. Screening for expression of bcl-2 may thus be useful to characterize leukemias regarding susceptibility to induction of apoptosis by different agents. The level of regulated c-myc expressed in these leukemias was not associated with susceptibility to induction of apoptosis. Transfection with a deregulated mutant p53 into the M1 leukemia did not change susceptibility to apoptosis induction, but transfection with deregulated c-myc increased susceptibility to apoptosis.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
JCOHome page
C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes
Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Biliran Jr., S. Banerjee, A. Thakur, F. H. Sarkar, A. Bollig, F. Ahmed, J. Wu, Y. Sun, and J. D. Liao
c-Myc Induced Chemosensitization Is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-{kappa}B Activity in Pancreatic Cancer Cells
Clin. Cancer Res., May 1, 2007; 13(9): 2811 - 2821.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Aneja, J. Zhou, B. Zhou, R. Chandra, and H. C. Joshi
Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.
Mol. Cancer Ther., September 1, 2006; 5(9): 2366 - 2377.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes
Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
A. A. A. M. Danen-van Oorschot, Y.-H. Zhang, S. R. Leliveld, J. L. Rohn, M. C. M. J. Seelen, M. W. Bolk, A. van Zon, S. J. Erkeland, J.-P. Abrahams, D. Mumberg, et al.
Importance of Nuclear Localization of Apoptin for Tumor-specific Induction of Apoptosis
J. Biol. Chem., July 18, 2003; 278(30): 27729 - 27736.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Bearss, R. J. Lee, D. A. Troyer, R. G. Pestell, and J. J. Windle
Differential Effects of p21WAF1/CIP1 Deficiency on MMTV-ras and MMTV-myc Mammary Tumor Properties
Cancer Res., April 1, 2002; 62(7): 2077 - 2084.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
D. Matas, A. Sigal, P. Stambolsky, M. Milyavsky, L. Weisz, D. Schwartz, N. Goldfinger, and V. Rotter
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis
EMBO J., August 1, 2001; 20(15): 4163 - 4172.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. C. Cusack Jr., R. Liu, M. Houston, K. Abendroth, P. J. Elliott, J. Adams, and A. S. Baldwin Jr.
Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341:: Implications for Systemic Nuclear Factor-{{kappa}}B Inhibition
Cancer Res., May 1, 2001; 61(9): 3535 - 3540.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Asher, J. Lotem, B. Cohen, L. Sachs, and Y. Shaul
Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1
PNAS, January 30, 2001; 98(3): 1188 - 1193.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Sigal and V. Rotter
Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome
Cancer Res., December 1, 2000; 60(24): 6788 - 6793.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
Y. Ohmura, M. Aoe, A. Andou, and N. Shimizu
Telomerase Activity and Bcl-2 Expression in Non-Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2000; 6(8): 2980 - 2987.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, A. Brunelli, G. Gorzegno, B. DiMarco, S. Aguggini, G. Bolsi, F. Cirillo, et al.
p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients
Clin. Cancer Res., July 1, 2000; 6(7): 2751 - 2758.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
T. Kondo, T. Matsuda, T. Kitano, A. Takahashi, M. Tashima, H. Ishikura, H. Umehara, N. Domae, T. Uchiyama, and T. Okazaki
Role of c-jun Expression Increased by Heat Shock- and Ceramide-activated Caspase-3 in HL-60 Cell Apoptosis: POSSIBLE INVOLVEMENT OF CERAMIDE IN HEAT SHOCK-INDUCED APOPTOSIS
J. Biol. Chem., March 17, 2000; 275(11): 7668 - 7676.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
P. Sabbatini and F. McCormick
Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis
J. Biol. Chem., August 20, 1999; 274(34): 24263 - 24269.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Wesselborg, I. H. Engels, E. Rossmann, M. Los, and K. Schulze-Osthoff
Anticancer Drugs Induce Caspase-8/FLICE Activation and Apoptosis in the Absence of CD95 Receptor/Ligand Interaction
Blood, May 1, 1999; 93(9): 3053 - 3063.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
C. Richardson, M. E. Moynahan, and M. Jasin
Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations
Genes & Dev., December 15, 1998; 12(24): 3831 - 3842.
[Abstract] [Full Text]


Home page
BloodHome page
C. E. Nesbit, S. Fan, H. Zhang, and E. V. Prochownik
Distinct Apoptotic Responses Imparted by c-myc and max
Blood, August 1, 1998; 92(3): 1003 - 1010.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
S. Moallem and B. Hales
The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations
Development, January 8, 1998; 125(16): 3225 - 3234.
[Abstract] [PDF]


Home page
J Biol ChemHome page
J. M. Garland and A. Halestrap
Energy Metabolism during Apoptosis: bcl-2 PROMOTES SURVIVAL IN HEMATOPOIETIC CELLS INDUCED TO APOPTOSE BY GROWTH FACTOR WITHDRAWAL BY STABILIZING A FORM OF METABOLIC ARREST
J. Biol. Chem., February 21, 1997; 272(8): 4680 - 4688.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. E. Banker, M. Groudine, T. Norwood, and F. R. Appelbaum
Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia
Blood, January 1, 1997; 89(1): 243 - 255.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
C. Thompson
Apoptosis in the pathogenesis and treatment of disease
Science, March 10, 1995; 267(5203): 1456 - 1462.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
A J Wagner, J M Kokontis, and N Hay
Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
Genes & Dev., December 1, 1994; 8(23): 2817 - 2830.
[Abstract] [PDF]


Home page
ScienceHome page
S. Lowe, S Bodis, A McClatchey, L Remington, H. Ruley, D. Fisher, D. Housman, and T Jacks
p53 status and the efficacy of cancer therapy in vivo
Science, November 4, 1994; 266(5186): 807 - 810.
[Abstract] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Asher, J. Lotem, B. Cohen, L. Sachs, and Y. Shaul
Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1
PNAS, January 23, 2001; (2001) 21558898.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1993 by the American Association of Cancer Research.